

GLAXOSMITHKLINE PLC  
Form 6-K  
July 13, 2016

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 12 July 2016

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes  No

--

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

Mr R G Connor

a) Name

b) Position/status

President, Global Manufacturing  
& Supply

c) Initial notification/  
amendment

Initial notification

2. Details of the issuer, emission allowance market participant, auction  
platform, auctioneer or auction monitor

a) Name

GlaxoSmithKline plc

b) LEI

5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of  
instrument; (ii) each type of transaction; (iii) each date; and (iv) each  
place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence  
each

ISIN: GB0009252882

b) Nature of the transaction

Acquisition of ordinary shares  
under the Company's  
ShareReward Plan

c) Price(s) and  
volume(s)

Price(s)	Volume(s)
£16.7127	7 (partnership shares)
	7 (matching shares)
£16.7127	

Aggregated information

d)

14 Ordinary shares

Aggregated volume Price

£16.7127

e) Date of the transaction

2016-07-11 (12:18 GMT)

f) Place of the transaction	London Stock Exchange (XLON)
-----------------------------	---------------------------------

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)  
Date: July 12, 2016

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc